115 related articles for article (PubMed ID: 1693375)
1. Plasma substance-P in neuroendocrine tumors and idiopathic flushing: the value of pentagastrin stimulation tests and the effects of somatostatin analog.
Vinik AI; Gonin J; England BG; Jackson T; McLeod MK; Cho K
J Clin Endocrinol Metab; 1990 Jun; 70(6):1702-9. PubMed ID: 1693375
[TBL] [Abstract][Full Text] [Related]
2. Effect of a long-acting somatostatin analogue (octreotide) on circulating tachykinins and the pentagastrin-induced carcinoid flush.
Balks HJ; Conlon JM; Creutzfeldt W; Stöckmann F
Eur J Clin Pharmacol; 1989; 36(2):133-7. PubMed ID: 2470592
[TBL] [Abstract][Full Text] [Related]
3. The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome.
Oberg K; Norheim I; Theodorsson E; Ahlman H; Lundqvist G; Wide L
J Clin Endocrinol Metab; 1989 Apr; 68(4):796-800. PubMed ID: 2466045
[TBL] [Abstract][Full Text] [Related]
4. Tachykinins in carcinoid tumors: their use as a tumor marker and possible role in the carcinoid flush.
Norheim I; Theodorsson-Norheim E; Brodin E; Oberg K
J Clin Endocrinol Metab; 1986 Sep; 63(3):605-12. PubMed ID: 2426299
[TBL] [Abstract][Full Text] [Related]
5. The pentagastrin test in the diagnosis of the carcinoid syndrome. Blockade of gastrointestinal symptoms by ketanserin.
Ahlman H; Dahlström A; Grönstad K; Tisell LE; Oberg K; Zinner MJ; Jaffe BM
Ann Surg; 1985 Jan; 201(1):81-6. PubMed ID: 2578277
[TBL] [Abstract][Full Text] [Related]
6. The pentagastrin test in the diagnosis of the carcinoid syndrome.
Ahlman H; Dahlström A; Grönstad K; Jaffe BM; Nilsson O; Oberg K
J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S86-8. PubMed ID: 2412067
[TBL] [Abstract][Full Text] [Related]
7. Circulating tachykinins (substance P, neurokinin A, neuropeptide K) and the carcinoid flush.
Conlon JM; Deacon CF; Richter G; Stöckmann F; Creutzfeldt W
Scand J Gastroenterol; 1987 Jan; 22(1):97-105. PubMed ID: 2882598
[TBL] [Abstract][Full Text] [Related]
8. Histamine release from a gastric carcinoid: provocation by pentagastrin and inhibition by somatostatin.
Roberts LJ; Bloomgarden ZT; Marney SR; Rabin D; Oates JA
Gastroenterology; 1983 Feb; 84(2):272-5. PubMed ID: 6184258
[TBL] [Abstract][Full Text] [Related]
9. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome.
Saslow SB; O'Brien MD; Camilleri M; von der Ohe M; Homburger HA; Klee GG; Pitot HC; Rubin J
Am J Gastroenterol; 1997 Dec; 92(12):2250-6. PubMed ID: 9399764
[TBL] [Abstract][Full Text] [Related]
10. Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors.
Feldman JM; O'Dorisio TM
Am J Med; 1986 Dec; 81(6B):41-8. PubMed ID: 2432780
[TBL] [Abstract][Full Text] [Related]
11. Neuropeptide K-(1-24)-peptide: storage and release by carcinoid tumors.
Conlon JM; Deacon CF; Grimelius L; Cedermark B; Murphy RF; Thim L; Creutzfeldt W
Peptides; 1988; 9(4):859-66. PubMed ID: 3226960
[TBL] [Abstract][Full Text] [Related]
12. Distinguishing features of idiopathic flushing and carcinoid syndrome.
Aldrich LB; Moattari AR; Vinik AI
Arch Intern Med; 1988 Dec; 148(12):2614-8. PubMed ID: 2461688
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels.
Milone F; Ramundo V; Chiofalo MG; Severino R; Paciolla I; Pezzullo L; Lombardi G; Colao A; Faggiano A
Clin Endocrinol (Oxf); 2010 Jul; 73(1):85-8. PubMed ID: 20039894
[TBL] [Abstract][Full Text] [Related]
14. Circulating bradykinin-like immunoreactivity and the pentagastrin-induced carcinoid flush.
Balks HJ; Conlon JM; Creutzfeldt W; Stöckmann F
Clin Endocrinol (Oxf); 1988 Aug; 29(2):141-51. PubMed ID: 3248356
[TBL] [Abstract][Full Text] [Related]
15. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
Kvols LK; Moertel CG; O'Connell MJ; Schutt AJ; Rubin J; Hahn RG
N Engl J Med; 1986 Sep; 315(11):663-6. PubMed ID: 2427948
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin, gastrointestinal peptides, and the carcinoid syndrome.
Long RG; Peters JR; Bloom SR; Brown MR; Vale W; Rivier JE; Grahame-Smith DG
Gut; 1981 Jul; 22(7):549-53. PubMed ID: 6114901
[TBL] [Abstract][Full Text] [Related]
17. The effect of a somatostatin analogue on the release of hormones from human midgut carcinoid tumour cells.
Wängberg B; Nilsson O; Theodorsson E; Dahlström A; Ahlman H
Br J Cancer; 1991 Jul; 64(1):23-8. PubMed ID: 1713051
[TBL] [Abstract][Full Text] [Related]
18. Use of somatostatin analog in management of carcinoid syndrome.
Vinik A; Moattari AR
Dig Dis Sci; 1989 Mar; 34(3 Suppl):14S-27S. PubMed ID: 2920654
[TBL] [Abstract][Full Text] [Related]
19. The effect of somatostatin on 5-hydroxytryptamine release from a carcinoid tumor.
Lawrence JP; Ishizuka J; Haber B; Townsend CM; Thompson JC
Surgery; 1990 Dec; 108(6):1131-4; discussion 1134-5. PubMed ID: 1978946
[TBL] [Abstract][Full Text] [Related]
20. [Effects of the administration of somatostatin 14 in the carcinoid syndrome. Clinical and biological study of 2 cases].
Guillard JF; Galmiche JP; Chayvialle JA; Kremer M; Comoy E; Lerebours E; Charbonnel B; Colin R
Gastroenterol Clin Biol; 1983 Dec; 7(12):1016-22. PubMed ID: 6141119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
